ATAI ATAI LIFE SCIENCES BV

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024.

Details of the company’s participation:

Format: Fireside Chat

Date and Time: Thursday June 6 at 10:00 A.M. ET

Location: New York

Webcast link:

The live webcast of the fireside chat will also be available on the Investors section of the atai website under . A replay will be available following the live event.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit .

Contact Information

Investor Contact:

Media Contact:



EN
31/05/2024

Underlying

ATAIATAI LIFE SCIENCES BV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ATAI LIFE SCIENCES BV

 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in...

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for Q2 2026BPL-003 was previously granted Breakthrough Therapy designation by the FDA for treatment-resistant depressionVirtual Investor Day scheduled on March 6, 2026, to provide further detail on the BPL-003 Phase 3 clinical strategy NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley In...

21h / 41m 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Announces Positive Topline Results from an Exploratory Pha...

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges’ g = 0.45; p-value = 0.036, one-tailed)EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) asses...

February 26, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

AtaiBeckley To Host Virtual Investor Day on March 6, 2026 NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will feature presentations and live Q&A sessions with members of the Company’s executive leadership team and several external key opinion leaders....

February 20, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

AtaiBeckley Appoints Michael Faerm as Chief Financial Officer NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chie...

February 19, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley To Participate in Upcoming Investor Conferences

AtaiBeckley To Participate in Upcoming Investor Conferences NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Jason Awe, Ph.D., Vice President of Investor Relations, will participate in fireside chats and host one-on-one meetings at the following investor conferences in March. TD Cowen ...

February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch